Zenkuda in Diabetic Retinopathy: Reduced the risk of developing sight- threatening complications by ≥85% in GLOW1 and GLOW2 GLOW1: Sham (n=125); Zenkuda (n=128). GLOW2: Sham (n=125); Zenkuda (n=130). Weighted percentages are based on weighted average of observed estimates across strata using CMH weights. p-values are based on the difference in response rates. Sight threatening complications include: diabetic macular edema, new or worsening proliferative diabetic retinopathy; anterior segment neovascularization; neovascularization of the disc and elsewhere, vitreous hemorrhage and neovascular glaucoma. GLOW1 GLOW2 21.0% 2.3% 0% 25% 50% Sham Zenkuda 15.8% 2.4% Sham Zenkuda Proportion of patients developing sight-threatening complications from Baseline through Week 48 89% risk reduction 85% risk reduction Phase 3 GLOW1 GLOW2 Superiority 6-month Durability 100% of patients on 6-month dosing at Year 1 29